Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:CRGX OTCMKTS:ETST NASDAQ:SOPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.84$1.74$1.05▼$5.17$199.33M0.27968,020 shs835,300 shsCRGXCARGO Therapeutics$4.47$4.50$3.00▼$25.45$216.17M0.31.73 million shsN/AETSTEarth Science Tech$0.19-5.0%$0.19$0.00▼$0.25$55.63M1.9199,938 shs5,840 shsSOPHSOPHiA GENETICS$3.23+1.9%$3.39$2.58▼$4.92$218.28M1.0171,880 shs20,533 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics-5.64%-11.54%-1.60%+31.43%+55.93%CRGXCARGO Therapeutics0.00%0.00%-1.54%+2.29%-79.84%ETSTEarth Science Tech0.00%+3.79%-2.44%+29.12%+24.92%SOPHSOPHiA GENETICS+1.60%-4.52%-8.65%+8.56%-20.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.84$1.74$1.05▼$5.17$199.33M0.27968,020 shs835,300 shsCRGXCARGO Therapeutics$4.47$4.50$3.00▼$25.45$216.17M0.31.73 million shsN/AETSTEarth Science Tech$0.19-5.0%$0.19$0.00▼$0.25$55.63M1.9199,938 shs5,840 shsSOPHSOPHiA GENETICS$3.23+1.9%$3.39$2.58▼$4.92$218.28M1.0171,880 shs20,533 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics-5.64%-11.54%-1.60%+31.43%+55.93%CRGXCARGO Therapeutics0.00%0.00%-1.54%+2.29%-79.84%ETSTEarth Science Tech0.00%+3.79%-2.44%+29.12%+24.92%SOPHSOPHiA GENETICS+1.60%-4.52%-8.65%+8.56%-20.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.11Buy$8.71369.77% UpsideCRGXCARGO Therapeutics 1.86Reduce$15.40244.52% UpsideETSTEarth Science Tech 0.00N/AN/AN/ASOPHSOPHiA GENETICS 3.00Buy$8.00150.39% UpsideCurrent Analyst Ratings BreakdownLatest ETST, SOPH, CRGX, and ACRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025ACRSAclaris TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$6.007/8/2025CRGXCARGO TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$3.70 ➝ $5.006/25/2025ACRSAclaris TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.006/23/2025ACRSAclaris TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$8.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$18.72M10.73N/AN/A$1.44 per share1.29CRGXCARGO TherapeuticsN/AN/AN/AN/A$4.91 per shareN/AETSTEarth Science Tech$33.12M1.68$0.01 per share17.28$0.01 per share19.00SOPHSOPHiA GENETICS$65.17M3.31N/AN/A$1.48 per share2.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$132.07M-$1.37N/AN/AN/A-802.03%-34.01%-24.18%11/5/2025 (Estimated)CRGXCARGO Therapeutics-$167.50M-$4.64N/AN/AN/AN/A-43.21%-37.26%11/11/2025 (Estimated)ETSTEarth Science Tech$3.25MN/A0.00∞N/A7.93%72.31%41.28%11/13/2025 (Estimated)SOPHSOPHiA GENETICS-$62.49M-$0.44N/AN/AN/A-40.99%-30.69%-17.39%11/4/2025 (Estimated)Latest ETST, SOPH, CRGX, and ACRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ACRSAclaris Therapeutics-$0.13-$0.13N/A-$0.13$1.34 million$1.78 million8/5/2025Q2 2025SOPHSOPHiA GENETICS-$0.25$0.33+$0.58$0.33$17.49 million$18.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/ACRGXCARGO TherapeuticsN/AN/AN/AN/AN/AETSTEarth Science TechN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A3.883.88CRGXCARGO TherapeuticsN/A12.3712.37ETSTEarth Science Tech0.010.910.67SOPHSOPHiA GENETICS0.623.393.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%CRGXCARGO Therapeutics93.16%ETSTEarth Science TechN/ASOPHSOPHiA GENETICS31.59%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics5.60%CRGXCARGO Therapeutics2.92%ETSTEarth Science Tech24.90%SOPHSOPHiA GENETICS4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100108.33 million102.27 millionOptionableCRGXCARGO Therapeutics11648.36 million46.95 millionN/AETSTEarth Science Tech3292.79 million221.02 millionNot OptionableSOPHSOPHiA GENETICS52067.58 million64.28 millionNot OptionableETST, SOPH, CRGX, and ACRS HeadlinesRecent News About These CompaniesSOPHiA Genetics & Jessa Ziekenhuis partner to bring cutting edge genomic testing and oncology research to cancer patients across BelgiumSeptember 8, 2025 | pharmabiz.comPJessa Ziekenhuis to adopt SOPHiA GENETICS platform for cancer careSeptember 8, 2025 | finance.yahoo.comShort Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Increases By 122.3%September 6, 2025 | marketbeat.comSOPHiA GENETICS and Jessa Ziekenhuis Announce Precision Oncology Partnership from the European Congress of PathologySeptember 5, 2025 | prnewswire.comSophia Genetics Growth Story Clouded By Persistent Losses: Why I'm Choosing To HoldAugust 26, 2025 | seekingalpha.comSOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Down 48.6% in JulyAugust 19, 2025 | marketbeat.comSOPHiA GENETICS SA: Positive Earnings Call HighlightsAugust 14, 2025 | theglobeandmail.comSOPHiA GENETICS Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS LagsAugust 7, 2025 | finance.yahoo.comSophia Genetics SA (SOPH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...August 7, 2025 | finance.yahoo.comSOPHiA GENETICS reaffirms $72M–$76M 2025 revenue guidance as AstraZeneca deal drives BioPharma outlookAugust 6, 2025 | msn.comSOPHiA GENETICS SA (SOPH) Q2 2025 Earnings Call TranscriptAugust 5, 2025 | seekingalpha.comSOPHiA GENETICS Reports Financial Results for Mid-2025August 5, 2025 | tipranks.comSOPHiA GENETICS Reports Second Quarter 2025 ResultsAugust 5, 2025 | prnewswire.comSOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomesAugust 5, 2025 | prnewswire.comSOPHiA GENETICS to Announce Financial Results for Second Quarter 2025 on August 5, 2025July 22, 2025 | prnewswire.comTurning Proof Into Power: Bioz Partners With SOPHiA GENETICS to Enhance Scientific Transparency via Custom IntegrationJuly 15, 2025 | pharmiweb.comPSophia Genetics launches podcast to decode data- and AI-driven medical innovationJune 27, 2025 | fiercepharma.comFAn end to an era: Supreme Court won't review IVF mixup rulingJune 26, 2025 | israelnationalnews.comIEnough hype about AI in health—let’s talk about resultsJune 12, 2025 | fastcompany.comFM42, AstraZeneca, and SOPHiA GENETICS launch UAE broad liquid biopsy initiative to transform cancer diagnosis and careJune 3, 2025 | zawya.comZM42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, careJune 3, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeETST, SOPH, CRGX, and ACRS Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$1.84 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.84 0.00 (0.00%) As of 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.CARGO Therapeutics NASDAQ:CRGX$4.47 0.00 (0.00%) As of 08/19/2025CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.Earth Science Tech OTCMKTS:ETST$0.19 -0.01 (-5.00%) As of 11:08 AM EasternEarth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.SOPHiA GENETICS NASDAQ:SOPH$3.23 +0.06 (+1.89%) Closing price 04:00 PM EasternExtended Trading$3.22 -0.02 (-0.46%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
